Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence

@article{Puranik2021ComparisonOT,
  title={Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence},
  author={Arjun Puranik and Patrick J. Lenehan and Eli Silvert and Michiel J. M. Niesen and Juan Corchado-Garc{\'i}a and John C O{\^a} Horo and Abinash Virk and Melanie D. Swift and John D. Halamka and Andrew D. Badley and A. J. Venkatakrishnan and V. Soundararajan},
  journal={medRxiv},
  year={2021}
}
Although clinical trials and real-world studies have affirmed the effectiveness and safety of the FDA-authorized COVID-19 vaccines, reports of breakthrough infections and persistent emergence of new variants highlight the need to vigilantly monitor the effectiveness of these vaccines. Here we compare the effectiveness of two full-length Spike protein-encoding mRNA vaccines from Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) in the Mayo Clinic Health System over time from January to July… 
COVID-19: vaccines, efficacy and effects on variants
TLDR
Three leading strategies of vaccine development against coronavirus disease 2019 (COVID- 19): mRNA vaccines, adenoviral vector vaccines and recombinant nanoparticles are reviewed and the evidence for the effectiveness of the vaccines against those five VoC is explored.
Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta
TLDR
An Omicron-specific mRNA vaccine was developed that restored protection against the original and the sublineages of OmicRON variant and broaden the protection spectrum of the new Omicrons mRNA vaccine, which paves the way to develop new vaccine candidate to target emerging variants in the future.
Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms
  • E. Gohda
  • Biology
    Journal of Disaster Research
  • 2022
TLDR
The efficacy of the two mRNA vaccines against COVID-19 with wild-type SARS-CoV-2 is more than 90% and is slightly decreased with the Delta variant, which is currently the predominant variant in many countries.
Chimeric mRNA based COVID-19 vaccine elicits potent neutralizing antibodies and protection against Omicron and Delta
TLDR
An Omicron-specific mRNA vaccine was developed that restored protection against the original and the sublineages of OmicRON variant and broaden the protection spectrum of the new Omicrons mRNA vaccine, which paves the way to develop new vaccine candidate to target emerging variants in the future.
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
Background: Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines was reported in studies in several countries, data is limited from Asian
Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting
TLDR
VE against infection after two doses of the mRNA vaccine was high initially, but significantly reduced against the delta variant for all three FDA approved vaccines.
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
TLDR
Findings show robust effectiveness for both BNT162b2 and mRNA-1273 in preventing Delta hospitalization and death in Qatar's population, despite lower effectiveness in preventing infection, particularly for the BNT 162b2 vaccine.
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
TLDR
It is important to keep medical literature updated with the ongoing trials of these vaccinations, especially as they are tested among different age groups and upon the emergence of novel variants of the SARS-CoV-2 coronavirus.
...
...

References

SHOWING 1-10 OF 23 REFERENCES
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
TLDR
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
TLDR
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
TLDR
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
TLDR
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
TLDR
Only modest differences in vaccine effectiveness were noted with the delta variant as compared with the alpha variant after the receipt of two vaccine doses, which would support efforts to maximize vaccine uptake with two doses among vulnerable populations.
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
TLDR
This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
TLDR
Sera from individuals having received one dose of Pfizer or AstraZeneca vaccines barely inhibited variant Delta, and it was found that variant Delta spread is associated with an escape to antibodies targeting non-RBD and RBD Spike epitopes.
...
...